Product Name:
MLK1-CT
Product Number:
ab-nk278-1
Target Full Name: Mixed-lineage protein-serine kinase 1; Mitogen-activated protein kinase kinase kinase 9
Target Alias: M3K9; MAPKKK9; MAP3K9; MLK-1; PRKE1; ENSG00000006432
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK278-1
Antibody Target Type: Pan-specific
Protein UniProt: P80192
Protein SigNET: P80192
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human MLK1 (MAP3K9) sequence peptide Cat. No.: PE-01BDX, PE-01BDY
Antibody Immunogen Sequence: CAELNTHRPAPYEIQQEFWS
Antibody Immunogen Description: Corresponds to amino acid residues A1086 to S1104; C-terminus
Production Method: Corresponds to amino acid residues A1086 to S1104; C-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 110-120 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No cross-reactivities detected in mouse brain, skeletal muscle, testes and thymus, or in various human cancer cell lines, including A431, HEK-293, HeLa, HepG2, Jurkat and MCF7 cells.
Related Product 1: MLK1-CT blocking peptide
Scientific Background: MLK1 (MAP3K9) is a protein-serine/threonine kinase of the TKL group and MLK family. It links to MAP kinases and will mediate activation of MKK/JNK via MAP2K4/MKK4 and MAP2K7/MKK7. Phosphorylation of T304, S308 and T312 increases MLK1's phosphotransferase activity. A mild effect on threonine phosphorylation and a minor impairment of JNK signalling can occur with a T305A mutation. Homodimerization via the leucine zipper domains is required for autophosphorylation and subsequent activation. The MKK/JNK pathway is involved in mediating release of cytochrome c from the mitochondria and inducing cell death via apoptosis. The MKK/JNK signalling pathway regulates stress response via activator protein-1 (Jun) and GATA4 transcription factors. It also plays a role in mitochondrial death signalling pathway, including the release cytochrome c, leading to cell death via apoptosis. MLK1 may be an oncoprotein (OP). In non-small-cell lung cancers, a gain of function has been observed with MLK1 (MAP3K9), which results in downstream activation of ERK1 and ERK2 MAP kinases.